Michael Foggs, MD
Allergy & Immunology · Chicago, ILNPI 1669490330
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $63,002 of the $71,176 with a category attached, or 88.5%. 18 manufacturers reported payments, led by Sanofi at 26.2% of the total. Reporting peaked in 2019 at $27,696 and has fallen 99.2% since, to $234 in 2024. Among allergy & immunology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $949.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$19K
- GSK$18K
- Boehringer Ingelheim$17K
- Novartis$9K
- AstraZeneca$8K
- Boehringer Ingelheim International GmbH$451
- plus $823 from 12 others
What the payments were for
- Consulting fees$63,00289%
- Speaking & faculty fees$2,8684%
- Travel & lodging$3,5665%
- Food & beverage$1,7402%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 11 | $18,680 |
| GSK | 6 | $17,722 |
| Boehringer Ingelheim | 7 | $16,882 |
| Novartis | 9 | $9,080 |
| AstraZeneca | 15 | $7,537 |
| Boehringer Ingelheim International GmbH | 1 | $451 |
| EMD Serono, Inc. | 10 | $238 |
| Alk-abello, Inc | 1 | $117 |
| Pfizer | 1 | $102 |
| Circassia Inc. | 1 | $95 |
| CSL Behring | 2 | $49 |
| Biogen | 2 | $49 |
| Amgen | 2 | $46 |
| Acadia Pharmaceuticals Inc | 3 | $41 |
| Argenx US, Inc. | 1 | $26 |
| Novo Nordisk | 1 | $25 |
| Bristol Myers Squibb | 1 | $23 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$18,420
- TRELEGY ELLIPTA$13,975
- STIOLTO RESPIMAT$13,342
- FASENRA$5,271
- SPIRIVA$3,540
- SPIRIVA RESPIMAT$451
- Odactra$117
- Ragwitek$117
- Grastek$117
- NUCALA$105
- EUCRISA$102
How this compares
$71,176 in reported general payments places this provider in the 90th percentile of 161 allergy & immunology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 28 | $849 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Chicago
- Anju PetersChicago$563K
- Giselle MosnaimChicago$331K
- Amanda SalihChicago$160K
- Juanita MoraChicago$147K
- Christina CiaccioChicago$73K
- Melanie MakhijaChicago$56K
- Whitney StevensChicago$34K
- Andrea Pappalardo WlochowiczChicago$33K
- Krishan ChhibaChicago$23K
- Sharmilee NyenhuisChicago$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.